Sign In
Buy MRVSY
$3.15
-0.0600 (-1.87%)
At Close: Jun 03, 2026
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
04:05pm, Monday, 01'st Jun 2026
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy Distinguished panel of experts in psychiatry and ne
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
04:05pm, Monday, 18'th May 2026
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv
Minerva S.A. (MRVSY) Q1 2026 Earnings Call Transcript
01:31pm, Friday, 08'th May 2026
Minerva S.A. (MRVSY) Q1 2026 Earnings Call Transcript
MINERVA FOODS REPORTS R$ 13.4 BILLION IN NET REVENUE IN THE FIRST QUARTER OF 2026
07:38pm, Wednesday, 06'th May 2026
For the 12 months ending in March 2026, the indicator totaled a record R$ 57 billion. EBITDA also reached a record annual level of R$ 5 billion.
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
08:00am, Tuesday, 05'th May 2026
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–
Minerva Announces Leadership Transition
04:05pm, Thursday, 02'nd Apr 2026
BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
04:05pm, Wednesday, 25'th Mar 2026
Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data
Minerva S.A. (MRVSY) Q4 2025 Earnings Call Transcript
06:52pm, Thursday, 19'th Mar 2026
Minerva S.A. (MRVSY) Q4 2025 Earnings Call Transcript
MINERVA FOODS REPORTS RECORD NET REVENUE OF R$ 54.8 BILLION IN 2025
08:04pm, Wednesday, 18'th Mar 2026
SÃO PAULO, March 18, 2026 /PRNewswire/ -- Minerva Foods (Minerva S.A. – B3: BEEF3 | OTC – Nasdaq International: MRVSY), a leader in fresh beef exports and its by-products in South America, also o
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
07:00am, Thursday, 12'th Mar 2026
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
07:00am, Wednesday, 11'th Mar 2026
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 Initiation of confirmatory Phase 3 tr
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
07:00am, Wednesday, 04'th Mar 2026
BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
08:30am, Wednesday, 19'th Nov 2025
Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will also serve as a consultant for roluperidone development.
